Elisabeth Stampa, Board Member at Medichem and President Medicines for Europe

With more than twenty years in the industry and as an experienced business leader with track record in growing and transforming businesses, Elisabeth serves currently at the Board of Medichem SA. She has been the former CEO of Medichem SA., transforming a pure API company into a competitive vertical integrated player. She held other executive positions at Corporate family business (Medichem SA and the former Combino Pharm SL), having started her career at Laboratorios Esteve. She holds a BSc in Pharmacy (UB, Spain) and a MBA (ESADE, Barcelona, Spain). She also serves on the Board of Trustees at the IQS in Barcelona. Elisabeth has been an active member of international associations throughout her professional career and advocates for legislative changes that improve patient accessibility and strengthen the European industry at a global level.

Stella Kyriakides, Commissioner for Health and Food safety, European Commission (Video Intervention)

As European Commissioner for Health and Food Safety, Stella Kyriakides has been leading the Commission's work on the public health response to COVID-19. Commissioner Kyriakides is responsible for a number of initiatives in the area of health aiming to establish a strong European Health Union. These include Europe's Beating Cancer Plan, the implementation of the EU Pharmaceutical Strategy, the proposal for a European Health Data Space and the operationalisation of the EU4Health Programme. She is a strong advocate for mental health. Commissioner Kyriakides is also responsible for the 'Farm to Fork' strategy for sustainable food, covering every step in the transformation of the food chain from production to consumption. Her responsibilities include animal welfare, food safety and animal and plant health and leading the work to protect plant health and reducing dependency on pesticides. Since February 2022, Commissioner Kyriakides has been at the forefront of EU efforts to support Ukraine and its people in the area of health, including by supporting the protection of the physical and mental health of Ukrainian refugees arriving in Member States. In 2006-2019, she was elected to the Cyprus Parliament for the Democratic Rally party, of which she was the Vice-President for ten years. In 2011, she was appointed Head of the Cyprus Delegation to the Parliamentary Assembly of the Council of Europe (PACE). In 2017, she was elected President of the PACE, the fourth woman to hold this position in the history of the Assembly. She has been an active advocate on patients' rights, and on the rights of cancer patients, founding the first Cypriot breast cancer organisation Europa Cyprus, for which she served as President for over 15 years. She was elected President to the European Breast Cancer Coalition Europa Donna, and served on numerous European patient advocacy and scientific boards. She is the recipient of numerous awards from her community service in Cyprus and globally.

Paul Neill, Chairperson, Medicines for Ireland, Country Manager, Teva Pharmaceuticals

Paul is the current Chairperson of Medicines for Ireland and also the Country Manager for Teva Pharmaceuticals Ireland. Paul has spend over 20 years in various commercial leadership roles in the Irish generics and biosimilar medicines industry.

Maja Graf, Associate Director Policy & Market Access, Medicines for Europe

Maja Graf is an Associate Director Policy & Market Access for Medicines for Europe, a leading trade association representing the generic, biosimilar, and value-added industries. With a strong background in pharmacy, Maja holds a Master of Sciences from the Faculty of Pharmacy, University of Ljubljana. In her role at Medicines for Europe, Maja focuses on ensuring equitable access to affordable treatments across Europe, promoting sustainable pharmaceutical markets for off-patent medicines, and driving treatment improvements throughout the medicines life cycle through Value Added Medicines. With her expertise and passion for improving healthcare, Maja is committed to increasing the health and wellbeing of all Europeans through better access to high-quality medicines.

Max Newton, Engagement Manager, IQVIA

Max Newton is an Engagement Manager at IQVIA with over 10 years of experience in the healthcare and pharmaceutical sector. Based in IQVIA's Basel office, Max leads a consulting team working with governments, industry associations, and medicines agencies on major healthcare system challenges to provide independent perspectives on issues ranging from medicines shortages to pricing and reimbursement issues. He is the author of many of IQVIA publications on the generic and biosimilar landscape, notably: The Prospects for Orphan Biosimilars (2020), The Biosimilar Scorecards (2020), Spotlight on Biosimilars (2021), The Biosimilar Void (2023), and Beneath the Surface: Unravelling the Value of Generic Medicines (2024), and has been the Project Lead for IQVIA's contributions to the DG SANTE's Multistakeholder Workshops and associated IQVIA report (The Impact of Biosimilar Competition in Europe) since 2019. Prior to joining IQVIA in 2016, Max worked at GSK, and in strategy consulting and is currently a guest lecturer at UCL's School of Pharmacy. Max holds a BSc in Medical Microbiology & Virology for Warwick University, and an MSc in Drug Discovery & Pharmaceutical Management from University College London.

Charles Gibbons, Director, Lachman Consultant Services

Charles Gibbons is a Director at Lachman Consultants with nearly 30 years of experience in the pharmaceutical industry. He is a Compliance and Auditing Professional who has been responsible for auditing manufacturing operations, commercial affiliates, key suppliers, and third-party manufacturing. Charles has also supported manufacturing sites by completing assessments and providing support for external regulatory agency inspections. He has provided leadership for auditing professionals. Charles developed audit schedules to ensure audits were consistently executed for all supplier types, such as, Third Party Manufacturers, Active Pharmaceutical Ingredients, Contract Laboratories, Logistics and Warehousing, excipients, commodities, medical device, and combination products. Mr. Gibbons is a founding member of the APIC/CEFIC Data Integrity Task Force and co-author of revision one and two of the APIC/CEFIC Practical risk-based guide for managing Data Integrity.

Deirdre Kelly, Vice-chair Medicines for Ireland, Country Manager Ireland and Malta, Consilient Health

Deirdre joined Consilient Health in 2014 to set up the Irish business unit. Since then, Deirdre and the Irish team have successfully launched a range of medicines across CH's key therapeutic areas in both the secondary and primary care settings with new launches in Malta from 2021. Prior to joining Consilient Health, Deirdre spent 13 years at Eli Lilly, most recently as business unit manager responsible for the Osteoporosis, Cardiology, Oncology and Primary Care product portfolios. At Novo Nordisk, she was the lead marketer for growth hormone in the UK & Ireland territories. Deirdre started her career at Nutricia where she held a number of management positions. Deirdre has a BSc (Hons) in Nutrition & Dietetics from Trinity College, Dublin with post graduate qualifications in marketing, health economics and a Diploma from the Institute Of Directors. Deirdre is also the vice chair and board member of Medicines For Ireland trade association, past director of the Irish Medicines Verification Organisation and past president of the Irish Pharmaceutical Managers Institute (2022 / 2023).

Prof Michael Barry, National Clinical Lead, Medicines Management Programme, Ireland

Prof. Michael Barry is a Consultant Clinical Pharmacologist and Head of the Department of Pharmacology & Therapeutics at the University of Dublin, Trinity College. He is the clinical director of the National Centre for Pharmacoeconomics which conducts pharmacoeconomic evaluations on medicines prior to reimbursement under the Community Drugs schemes in Ireland. He is Past-President (2010-2011) of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). He was a board member of the Health Information and Quality Authority (HIQA) and is a member of a number of National Committees on pricing and reimbursement of medicines.

Prof. Barry chairs the New Drugs Committee and the Medication Safety Committee at St. James's Hospital, Dublin. In 2013 he was appointed as Clinical Lead for the new HSE Medicines Management Programme. He is a fellow of the Royal College of Physicians in Ireland and is a specialty trainer for Pharmacology & Therapeutics. His research areas include the cost-effectiveness of high cost drugs including chemotherapeutic agents and biologic drugs, pricing and reimbursement and performance based risk sharing schemes. He has published widely on the cost-effectiveness of medicines in the Irish healthcare setting.

Arnaud Mahéas, Chair of Generic Market Access Committee, Medicines for Europe, Head Public Affairs Europe, Sandoz

Arnaud is the Head of Public Affairs Europe at Sandoz. He is responsible for public and government affairs at the EU and national levels in more than 40 countries. His focus is to expand patient access, regain pricing flexibility, promote smart procurement and resilient supply for generic and biosimilar medicines. Since 2023, he chairs the Generic Medicines Market Access Committee at Medicines for Europe. Arnaud is a highly experienced public affairs professional with a successful track record across multiple industries. He built and led the European public affairs practice at Servier. And prior to joining the healthcare industry 15 years ago, he headed the EU representation of the French national railway company (SNCF) and later managed strategic relations with the EU for the association of the top 100 companies operating in France (AFEP). Arnaud holds a Master of Arts in European Administration and Politics from the College of Europe in Bruges and degrees in European Law and Government Affairs from the University of Rennes and Sciences Po Rennes.

Victor Mendonça, Head of Corporate Affairs, Viatris and member of Medicines for Europe Board

Victor Lino Mendonça is the Head of Corporate Affairs for Viatris in Europe and Board member of Medicines for Europe. Formerly, he was leading the Health Economics department at Medicines for Europe. He was also Advisor to the Executive Board of INFARMED for almost 8 years and prior to this, was the Advisor to the Health Secretary of State to the Ministry of Health in Portugal. He has more than 20 years of experience in pharmaceuticals sector having also worked in FMCG sector. Victor graduated in Business Administration by Universidade Católica Portuguesa in Portugal.

Emer Cooke, Executive Director, European Medicines Agency (Video Intervention)

Emer Cooke began her mandate as Executive Director of EMA on 16 November 2020. Ms Emer Cooke has over 30 years of experience in international regulatory affairs, with more than 18 of these in leadership roles.

Before taking up her current role, she was the Director responsible for all medical product related regulatory activities at the World Health Organization (WHO) in Geneva between November 2016 and November 2020. Ms Cooke worked at EMA between 2002 and 2016. She joined the Agency as Head of Inspections and became Head of International Affairs in 2009. Prior to that, she was Principal Administrator in the Pharmaceuticals Unit of the European Commission between 1998 and 2002, with responsibility for inter alia, inspections, international activities including enlargement of the EU and selected legislative initiatives. Ms Cooke worked for the European Federation of Pharmaceutical industries and Associations (EFPIA) as Manager of Scientific and Regulatory Affairs from 1992 to 1995 and part time from 1996 to 1998. She also worked part time as an independent pharmaceutical policy advisor, based in the Czech Republic, from 1996 to 1998. Ms. Cooke held a number of roles within the Irish pharmaceutical sector between 1985 and 1990 including two years as a pharmaceutical assessor at the Irish medicines regulatory authority. Ms. Cooke holds a degree in pharmacy and two master's degrees in science and in business administration from Trinity College Dublin, Ireland. She is an Irish national.

Olivier Girard, DG HERA, European Commission

Olivier is the Head of Unit for Medical Counter Measures in the Health Emergency Preparedness and Response Authority (HERA) of the European Union since 2022. He joined the European Commission in 2003, after beginning his career as a qualified FR/UK attorney specialising in banking and capital markets in London and in Paris. After having worked on financial services, single market and industrial policies in various functions, he was since 2018 Head of Unit in the Secretariat-general of the Commission in charge of industrial policy, research and innovation and the single market. His focus is on supporting development, manufacturing, access to and supply of medical countermeasures in the EU. He is also in charge of the Critical Medicines Alliance, an industrial alliance for the security of supply of critical medicines in the EU which was set up in April 2024.

Clare Fitzell, Head of Strategic Policy, IPU and member of PGEU Executive Board

Clare is a pharmacist with over 20 years of experience in community-based practice. She has a wide range of experience in areas of pharmacy service delivery, regulatory affairs and managing quality in pharmacy practice. In her current leadership position as Head of Strategic Policy at the IPU, Clare is responsible for advocating for advanced practice and developing strategies to support community pharmacists to practice to their full scope. Clare actively participates and advocates on behalf of community pharmacists at a European level and currently sits as a member of the Executive Committee of the Pharmaceutical Group of the European Union (PGEU). Clare enjoys sharing her expertise and knowledge of community pharmacy practice and works across a wide range of multi-disciplinary teams and committees. She currently sits on the APPEL Strategic Advisory Group, IIOP Advisory Group, the Irish Heart Foundation Blood Pressure Council and Pharmacy eHealth Group.

Philippe Drechsle - Vice President EU Portfolio, Teva & member of the Medicines for Europe executive committee

Economist and certified accountant by education, Philippe has been working in the generics industry for over 25 years in various functions spanning from controlling/finance, demand management, product administration, area management, business development, product portfolio optimization, to special projects such as FMD project lead. He is currently responsible for EU Portfolio, in charge of generics product selection, launches and life-cycle management.

Ellen McGrath, Medicines Shortages Coordination Lead, Health Products Regulatory Authority (HPRA)

Ismail Nayef Khdeir, Senior Strategic Specialist, Amgros

More than 13 years of extensive experience in procurement of pharmaceuticals from my time in Amgros I/S, the centralized procurement body for hospital medicines in Denmark. Specialized in strategically planning and executing EU tenders and negotiation of pharmaceutical products. With the aim to secure the right medicines for patients at public hospitals. At the right time, at the right place, at the right price, and always with an eye to protecting the environment. Some of the responsibility encompass collecting vital information on the pharmaceutical market, patent expirations and orchestrating tender processes to optimize cost-effectiveness. Furthermore, works with integrating MEAT criteria into our tender evaluations, with a special focus on emphasizing initiatives that strengthen supply chain resilience. Member of the expert group under the European Commission's National Competent Authorities on pricing and reimbursement and public healthcare payers (NCAPR) to develop best practice guidance for public procurement to better support security of supply and availability of medicinal products. Education: Master of Business Administration (MBA), Middlesex University London, Master of Science (MSc.) in Pharmacy (Pharmacist), University of Copenhagen, Bachelor of Science (BSc.) in Pharmacy, University of Copenhagen, Academy Profession (AP), Degree in Business Economics, Niels Brock Copenhagen.

Adrian van den Hoven, Director General, Medicines for Europe

Adrian van den Hoven has been director general of Medicines for Europe since September 2013. In his role he focuses on stimulating competition in off-patent medicine markets, fostering access to medicine, reducing medicine shortages and addressing major health crises, supporting policy measures for sustainable pricing, promoting efficient regulatory standards, and developing a coherent EU industrial strategy to support the long-term viability of the generic, biosimilar and value-added medicines industries. He is also member, and former president, of the European Medicines Verification Organization (EMVO) board for the implementation of serialization against falsified medicines, the Chair of the International Generic and Biosimilar medicines Association (IGBA) and a member of the joint industry advisory council of the Health Emergency and Response Authority (HERA).

Aidan Fry, Director External Communications, STADA

Aidan Fry is Director of External Communications at STADA Arzneimittel. In this role, which he has held since February 2020, Aidan oversees communications with key stakeholders across the group's 120-plus markets and activities encompassing generics, specialty medicines and consumer healthcare products. He also coordinates STADA's participation in key industry associations, including Medicines for Europe and the International Generic and Biosimilar medicines Association. Aidan has more than 20 years of experience in the off-patent medicines sector, including as a co-founder and editor of Generics Bulletin, the industry-leading business-to-business newsletter.

Tom Roane, Vice President, Corporate Engagement & Strategy, Direct Relief

Tom Roane serves as Vice President of Corporate Engagement & Strategy for the global medical relief non-profit Direct Relief, an organization founded over 70 years ago which will provide over $2 Billion this year in donated medical products to vetted and qualified public hospitals and clinics in over 100 countries around the world, including within Europe and the United States. Roane has over two decade's experience in establishing and managing Rx access and medical support programs in all regions of the world to help underserved patients access their required treatments, as well as 8 years' experience in business development and marketing management with big pharma and start up biotechnology companies. His expertise in the design and implementation of creative and impactful ESG programs have opened opportunities for drug access for underserved patients with cancer, diabetes, rare disease, and non-communicable diseases. All of the world's largest pharmaceutical corporations have trusted relationships with Direct Relief, which has become the largest global non-profit provider of humanitarian medical relief for the world's at-risk and underserved, including in Ukraine where Direct Relief is working hand in hand with the country's health ministry and other strategic partners in providing into Ukraine many hundreds of tons of requested and required vital medical products.

Adele Paterson, CEO, International Health Partners

As CEO of the global health charity, International Health Partners (IHP), Adele Paterson leads its work to increase access to essential healthcare products for vulnerable communities around the world. Since taking over as CEO in 2017, the organisation has seen its size double and its impact increase tenfold. During her tenure, IHP has delivered over £112.7 million worth of medical products to those in need, showcasing her commitment to improving global health outcomes. Adele oversees a comprehensive range of health programmes that address various critical needs, including disaster response, mental health, cancer, non-communicable diseases, neglected tropical diseases, and primary healthcare.
Adele holds a degree in Economics and Politics and began her career as a political researcher, managing the parliamentary office of a UK government minister. Before joining IHP, Adele served as the head of policy for a financial trade association, and led CSR, fundraising, and communications for a national regeneration charity, bringing a wealth of experience in strategic leadership and stakeholder engagement. Adele is Treasurer of Integral Alliance, a union of 22 global disaster response agencies, and sits on the Board of the Anglican Communion Fund supporting the international ministry of the Archbishop of Canterbury in 165 countries.

Raluca Radu, Senior Manager Value Added Medicines Policy

Raluca works currently as Senior Manager for Value Added Medicines Policy at Medicines for Europe. In her current role she combines her scientific background from her training as a pharmacist, with her passion for health and regulatory policy. In her daily work Raluca focuses on advocating for policies which create a supportive environment for innovation in the off-patent space, allowing us to capitalise on the full potential of existing medicines, and shift to a more sustainable drug development pathway.

James Burt, Chair of Value Added Medicines Sector Group, CEO of Pharmanovia

James joined Pharmanovia in October 2021. Before joining he was the Executive Vice President EMENA at Accord Healthcare and oversaw branded and generic pharmaceutical activities across 65 markets. Prior to this, he served as Vice President Hospital Business at Actavis, where he was responsible for the strategic direction of secondary-care activities worldwide. He holds a PhD in Chemical Engineering from the University of Birmingham, with a particular focus on biopharmaceutical manufacturing. James is Chair of the Medicines for Europe, Value Added Medicines Sector Group.

Tanya Mulcahy, Director of Health Innovation Hub Ireland and Founder of FemTech Ireland

Tanya is Director of Health Innovation Hub Ireland (HIHI) and founder of Ireland's first FemTech Ecosystem. She graduated from University College Cork with an honours degree in Biochemistry before completing a PhD in Cancer Genetics followed by postdoctoral research in Trinity College Dublin, in the field of Neuropsychiatric Genetics. In addition to her roles in academia and the public sector in Ireland, Tanya has held positions in Research and Development in the Pharma the Biotech Start-up industry in the USA. In 2021 she was appointed by the Minister for Health to the HPRA Medical Device Advisory Committee, she is an Advisory Committee member of the National Clinical Trials Office (NCTO) and she is an independent advisor to a number of HealthTech start-ups. She is particularly interested in supporting female founders and those innovating in women's health. Health Innovation Hub Ireland is a national initiative supported by Enterprise Ireland and the HSE and led by University College Cork, HIHI supports the development of innovative healthcare solutions and supports the implementation of these within the Irish healthcare system, supporting the economy, the healthcare system and the citizens of Ireland.

Stefano Collatina, Country Lead, Italy and Pharmaceuticals Business Unit Head Southern Europe, Baxter

Stefano is a Physician and Manager in the Healthcare sector. His experiences are at the intersection between medicine, technology, and the management of complex organizations. Since 2019, Stefano has been Country Lead of Baxter S.p.A., the Italian subsidiary of Baxter Healthcare, a global leader in the Pharmaceutical and MedTech sector, with a turnover of $15 billion and 60,000 employees. In Baxter, Stefano also holds the role of Head of the Pharmaceutical Business Unit for Central and South Europe, with business responsibility for the main European markets (Italy, France, Spain, Portugal, Greece, and Benelux). In the last 14 years at Baxter, Stefano has held management positions in Italy and in other European countries, including Market Access & Institutional Relations; Patient support Programs; Operations; Hospital Division Head; Integrated Care Solutions & Digital Health. In all positions, he has consistently met or exceeded budget and revenue targets. Before Baxter, Stefano worked in Bristol-Myers Squibb, both in Italy, as Medical Director (he was involved, among other things, in the development of innovative drugs in the cardiology and internal medicine area), and in the USA, as Medical- Marketing Director. Subsequently, he served as Medical Director for Merck Sharpe & Dohme and as Business Unit Director for Schering AG where he gathered extensive experience in Multiple Sclerosis and related patient support programs. At the institutional level, Stefano represents Baxter Healthcare in Italy and in Europe. Stefano is the President of EGUALIA, an association of Pharmaceutical Industries that brings together 70 companies of generic medicines and Biosimilars.

Lisa Wynne, Parkinson's Nurse Specialist, a member of the Parkinson's Europe Research Steering Group and a member of Parkinson's Ireland

Lisa is an accomplished Parkinson's Nurse Specialist with over a decade of experience, pivotal in shaping Parkinson's Ireland's nurse service. Her approach emphasizes empowerment and education through initiatives like public lectures and online seminars. She's dedicated to raising awareness and dispelling misconceptions about Parkinson's through media engagement. Lisa's international collaborations advance PD research and treatment modalities. As Vice Chairperson of the Research & Impact Subcommittee of PI, she drives critical research agendas. Her recent completion of a CPD module reflects her commitment to staying current in PD care. Lisa's contributions have significantly improved support and resources for those affected by Parkinson's in Ireland and globally.

Olga Solomon, Head of Unit D1 Medicines: policy, authorisation and monitoring, DG Santé, European Commission

I hold a degree in Chemistry from the University of Thessaloniki and a Master's degree in Food Science from the University of Gothenburg. My professional journey has shaped my expertise in various domains. Following my five-year experience at a prominent beverage company in Greece, I joined the European Commission in 2001. Over two decades, I gained experience in the field of food safety, in areas such as food additives, enzymes, and food contact materials and in the past 12 years in the area of pharmaceuticals. Since May 2017, I am Head of Unit SANTE D.1 'Medicines: policy, authorisation, and monitoring' and have taken up the role of acting Director in SANTE D: 'Medical products and Innovation' since March 2023. My professional journey has equipped me with extensive knowledge and skills in health policies, risk assessment, management and communication. Throughout my career, I have navigated complex stakeholder landscapes and negotiated with the European Parliament and the Council on proposals related to food and pharmaceuticals. In close collaboration with Member States and European Agencies, such as the European Food Safety Authority and the European Medicines Agency, I have fostered fruitful partnerships. Beyond the European stage, my influence has extended to international forums. Notably, I successfully negotiated food standards within the Codex Alimentarius and spearheaded activities pertaining to bilateral and multilateral relations with global partners in the pharmaceutical field. I have guided my team through preparedness and crisis management activities during crucial events such as Brexit and the COVID-19 pandemic, including the expedited authorisation of vaccines and therapeutics. One of my notable achievements lies in my pivotal role in shaping the Pharmaceutical Strategy for Europe. Moreover, I led the implementation of this strategy, including the adoption in April 2023 of a comprehensive package of proposals for the revision of the pharmaceutical legislation.

Silke Oeschger-Delautre, Corporate Communication Lead Europe, Dr. Reddy's Laboratories

Silke leads Corporate Communication for Dr. Reddy's generic business in Europe and its API and Service unit. She also supports the company's ESG and public health initiatives and volunteers for the PSCI (Pharmaceutical Supply Chain Initiatives) for more sustainable supply chains. Silke has worked in the pharma sector for over 20 years and brings a blend of marketing, corporate communication, analytical R&D, and quality management expertise to her role. Before joining Dr. Reddy's in 2015, she was with companies such as Genedata, Solvias, Carbogen Amcis, Knoll/BASF Pharma, and Vetter Pharma.

Keith Moore, Programme Coordinator, Sustainable Healthcare Coalition

Keith Moore is an established environmental and sustainability professional with over 25 years' experience. Before taking up the role of Programme Coordinator at Sustainable Healthcare Coalition, he was AstraZeneca's lead on carbon and climate strategy helping the company achieve "A-list" on the CDP annual corporate benchmarking programme and inclusion in both the FTSE4Good and Dow Jones Sustainability Indices. The Sustainable Healthcare Coalition is a healthcare sector led group that looks for the greatest opportunities to inspire sustainable practices in healthcare through the collaboration of its members.

Courtney Soulsby, Global Director Healthcare and Life Sciences Sector, BSI

Courtney Soulsby works as a Global Director for the Healthcare and Life Sciences sector team for BSI (British Standards Institution), focusing on healthcare sustainability. Courtney has worked with pharmaceutical and med tech industries and their supply chains for over ten years – with a deep understanding the issues with regulation, environment, security, compliance, quality, and other risk exposures when manufacturing and transporting medicines.

Ines Windisch, Head of Communications, Corporate Affairs & Sustainability, Zentiva Group

Recognized as a highly experienced leader who spent almost 30 years in the healthcare industry in various areas like Communications, Corporate Affairs, Marketing & Sales, Market Access, Human Resources and Sustainability, locally, regionally and globally. While focusing on change management, organizational excellence, and stakeholder management I have proven performance in successful integration and transformation projects in small startups and in larger organizations. I am engaging the targeted community with drive, passion, creativity, and personalized communication. Strong track record in building teams, strengthening corporate culture and identity, and transforming organizations from good to great. During the last 6 years I am part of the exciting journey at Zentiva that started with the carve out from Sanofi. Together with 5000 colleagues across Europe and in India we have doubled the company, strengthened our resilience and are enjoying our time together in a great place to work. I am passionate about making a difference by engaging people to take better care of our impact on the society and our planet. In my private life I am a proud Austrian, who has decided to live in the most beautiful place on earth, enjoying my free time with my family discovering our beautiful nature.

Maja Anette Fløtnes Monsen, Norwegian Hospital Procurement Fund, Skyehusinnkop

Maja Anette Fløtnes Monsen is an experienced pharmacist, creative author, and poet. She is currently working for the Norwegian hospital procurement trust, where she, in the last seven years, has had a leading role in including environmental criteria in medicines tenders in Norway and the Nordic countries. Her responsibility has been to provide the best agreements for a total of 90% of the medicines daily used in Norwegian hospitals. The inclusion of environmental criteria arrived both from a need for change in the long-term strategic planning to secure the supply chain, and from a governmental focus on combating antibiotic resistance and changing environmental impact. Maja has written, tested, evaluated, and scored different environmental criteria on a large scale, over a big range of different medicines and suppliers. The work has given her a unique insight and expertise in how to drive changes, and approach sustainability in the tender process for medicines.

Pierluigi Antonelli, President and CEO, Fresenius Kabi

Pierluigi Antonelli is the President and CEO of Fresenius Kabi since March 2023. He has extensive operational expertise in the healthcare industry, with a focus on product development, launch of new products in key international markets, business & strategy development. In his previous position, he served as CEO of Angelini Pharma, a company specialized in Brain Health and Consumer Health, since 2019. Prior to that, he held senior positions at companies such as Novartis

Oncology, Sandoz, Merck & Co, and Bristol-Myers Squibb in the United States and Europe, after working few years in McKinsey & Company. He holds an MBA from Kellogg School of Management and a degree in Economics from L.U.I.S.S..

Markus Sieger, CEO, Polpharma Group

Markus Sieger has been active in emerging markets and emerging industries for over 30 years. During this time, he has focused on building and developing companies in the pharmaceutical, media, fast-moving consumer goods and real estate industries, by managing complex and strategic transactions in the USA, CEE, CIS and Singapore. He has been a member of supervisory boards of private and public companies and is currently the chairman of Cyclo Therapeutics (NASDAQ:CYTH). He has been associated with Polpharma Group since 2000 and was appointed CEO of Polpharma Group in June 2016. In 2018, he joined the Executive Committee of Medicines for Europe. He is an alumnus of Stanford University Graduate School of Business.

Rebecca Guntern, President Sandoz Europe

Rebecca Guntern is the president of Sandoz Europe and member of the executive committee. Region Europe spans across more than 40 countries on the continent and delivered sales in 2023 of 5 bn USD. She is a senior business leader with over 25 years of international experience in the pharmaceutical and healthcare industry. She joined Sandoz in 2007 as Head of Sales and has held positions of increasing leadership responsibility since then. Prior to joining Sand oz, Rebecca Guntern worked for other leading pharmaceutical companies such as Roche and Merck Sharpe & Dohme. Rebecca Guntern serves as vice president of Medicines for Europe (MfE) and is a member of the board of directors at BKW AG Switzerland, where she is heading the compensation committee. She holds a master's degree in pharmacy from the University of Basel as well as a bachelor's degree in business administration.

Stephan Eder, Executive Vice President Western Europe & Germany, STADA

Stephan Eder has more than 15 years of experience in the healthcare industry. He has been a member of STADA's global management team since 2020 and is responsible for Western European markets, including Germany. Before joining STADA, Stephan Eder held various international management positions at Novartis, Sandoz and Hexal.

Artur Cwiok, Head of Europe, Viatris

With a career spanning over three decades in the pharmaceutical industry, Dr. Cwiok has consistently demonstrated his expertise and dynamic leadership, influencing the industry and making a significant impact on the healthcare landscape. A qualified doctor with an extensive background in the pharmaceutical sector, Dr. Cwiok has held senior roles across Europe, in the specialty sector where he has experience across multiple channels. From generics to brands, OTC to prescription, retail to hospital, mature to innovative therapies, his strategic vision has propelled organizations to success. Currently serving as the Head of Europe for Viatris, a global healthcare company dedicated to empowering people worldwide to live healthier at every stage of life. Viatris operates in 38 countries within the European region and has an expanded reach to more than 165 countries and territories across the globe. A true advocate for universal healthcare, Dr. Cwiok has been playing an active role in various national and regional industry associations with the goal of ensuring unfettered access to high-quality medicine for European populations. As a Member of the Executive Committee for Medicines for Europe, Dr. Cwiok is privileged to be part of an organization responsible for shaping a future where the health and well-being of all are prioritized. Driven by an unwavering passion, Dr. Cwiok believes in providing everyone with the opportunity to live a full and healthy life and he tirelessly strives for a future where optimal health is within reach for all.

Steffen Saltofte, CEO, Zentiva

Steffen Saltofte is a passionate and focused leader with an exceptional track record in strategic growth. He serves as the CEO of Zentiva Group, where he leads a dedicated team of 5,000 associates across more than 30 countries, committed to delivering high-quality and affordable medicines globally. His leadership is marked by a strong commitment to sustainability and the creation of a dynamic corporate culture. Steffen's career spans various senior executive roles. Steffen joined from Acino where he was CEO, prior to that he has held key positions at Boehringer Ingelheim, Merial (a Sanofi Company), Syngenta, and Maersk Line, where he demonstrated his expertise in global commercial operations, business development, and change management. Steffen holds an MBA from IMD and bachelor's degrees in International Business and Strategic Market Management from Copenhagen Business School, as well as a Bachelor's in Shipping from the Institute of Chartered Shipbrokers. Fluent in Danish and English, with proficiency in Swedish and German, Steffen brings a global perspective to his leadership approach. Under his guidance, Zentiva continues to thrive as a leader in the pharmaceutical industry in Europe, delivering on its promise of accessible healthcare while fostering a culture of innovation and excellence. Steffen's dedication to sustainability and quality ensures that Zentiva remains at the forefront of the industry and providing health and wellbeing to more than 100 million people in Europe and beyond.

Colm Burke TD, Minister of State with responsibility for Public Health, Wellbeing and the National Drugs Strategy

Colm Burke is Minister of State at the Department of Health with special responsibility for Public Health, Wellbeing and the National Drugs Strategy. He was appointed to this role on 10 April 2024. The role includes the promotion of healthier lifestyles and policies to improve the health of people in Ireland. He was elected as a TD (member of Parliament) for Cork North Central in 2020. He was previously a Senator (2011-2020) and was elected on the Industrial and Commercial Panel.